NewAmsterdam Pharma Co Stock (NASDAQ: NAMS)

NewAmsterdam Pharma Co

NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACEL

CART

CDNA

FLYW

LBTYK

LMND

NAMS

SGRY

ZETA

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

AAMI

AXON

CLIK

ENVB

HCTI

ICCT

PITA

PRCH

SMCI

Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Portland,,Oregon,-may,11,2019:,Southwest,Airlines,Passenger,Planes,At

ANIP

CFFI

RLGT

SIBN

SLXN

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co NV

NewAmsterdam Pharma Company N.V. - Warrant

NamSys Inc

Press Releases

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Financing

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

Health Care

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

General

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Earnings

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAMSW

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

ImmunityBio

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

Scotiabank

Needham

RBC Capital

HC Wainwright & Co.

Comments

NewAmsterdam Pharma Co

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga